Cellectis to Participate in Upcoming Investor Conferences
02 Settembre 2020 - 10:57PM
Cellectis to Participate in Upcoming Investor Conferences
Cellectis (Euronext Growth: ALCLS - Nasdaq: CLLS), a clinical-stage
biopharmaceutical company focused on developing immunotherapies
based on gene-edited allogeneic CAR T-cells (UCART), will present
at several upcoming investor conferences. Webcast information when
available will be posted in the Investor Relations section of the
Company’s website
at https://www.cellectis.com/en/investors/events-and-webcasts/
Citi Annual BioPharma Conference September 9,
2020 from 3:20 PM to 4:05 PM EDTAndré Choulika, Chairman & CEO,
to participate in a panel on Innovation in Cell Therapy.
Wells Fargo Healthcare Conference Boston
September 10, 2020 from 8:00 AM to 8:30 AM EDTAndré Choulika;
Carrie Brownstein, CMO; Simon Harnest, VP, Corporate Strategy &
Finance to provide a company presentation.
Baird’s 2020 Global Healthcare Conference
September 10, 2020 at 3:10 PM EDTSimon Harnest to participate in a
firechat and a live Q&A.
Bank of America Healthcare Conference London
September 17, 2020 from 4:55 AM to 5:45 AM EDTAndré Choulika to
provide a company presentation.
About CellectisCellectis is
developing the first of its kind allogeneic approach for CAR-T
immunotherapies in oncology, pioneering the concept of
off-the-shelf and ready-to-use gene-edited CAR T-cells to treat
cancer patients. As a clinical-stage biopharmaceutical company with
over 20 years of expertise in gene editing, Cellectis is developing
life-changing product candidates utilizing TALEN®, its gene editing
technology, and PulseAgile, its pioneering electroporation system
to harness the power of the immune system in order to target and
eradicate cancer cells.
As part of its commitment to a cure, Cellectis
remains dedicated to its goal of providing life-saving UCART
product candidates to address unmet needs for multiple cancers
including acute myeloid leukemia (AML), B-cell acute lymphoblastic
leukemia (B-ALL) and multiple myeloma (MM).
Cellectis headquarters are in Paris, France,
with additional locations in New York, New York and Raleigh, North
Carolina. Cellectis is listed on the Nasdaq Global Market (ticker:
CLLS) and on Euronext Growth (ticker: ALCLS). For more information,
visit www.cellectis.com.
Follow Cellectis on social media: @cellectis,
LinkedIn and YouTube.
TALEN® is a registered trademark owned by
Cellectis.
For further information, please
contact:
Media contacts:Jennifer Moore,
VP of Communications, 917-580-1088, media@cellectis.comCaitlin
Kasunich, KCSA Strategic Communications, 212-896-1241,
ckasunich@kcsa.com
IR contact:Simon Harnest, VP of
Corporate Strategy and Finance, 646-385-9008,
simon.harnest@cellectis.com
PDF available
at: http://ml.globenewswire.com/Resource/Download/32cc4faa-c739-4269-ac06-216bf9f2266d
Grafico Azioni Cellectis Nom Eo 05 (EU:ALCLS)
Storico
Da Mar 2024 a Apr 2024
Grafico Azioni Cellectis Nom Eo 05 (EU:ALCLS)
Storico
Da Apr 2023 a Apr 2024